Abraxane annual sales peak?

What drove Abraxane's sales growth?

Abraxane, a chemotherapy medication, saw significant growth in annual sales, primarily due to its approval for treating breast cancer [1]. As an albumin-bound paclitaxel nanoparticle, Abraxane offers a unique delivery mechanism that can improve the efficacy of paclitaxel while reducing side effects [2].

Breast cancer applications

In 2005, Abraxane was first approved by the FDA for the treatment of breast cancer resistant to anthracyclines and taxanes. This targeted indication has been instrumental in driving Abraxane's sales, particularly in the metastatic setting [3].

Other applications and pipeline expansion

In addition to breast cancer, Abraxane has also gained approval for treatment of non-small cell lung cancer (NSCLC), pancreatic cancer, and adenocarcinoma of the stomach or gastroesophageal junction. Abraxane's development in these areas has also contributed to its growing revenue [4].

Sales peak

According to a report, Abraxane's annual sales peaked in 2015, with revenue reaching approximately $1 billion [1]. This marked a significant increase from its earlier sales, which were around $200 million in 2009.

Impact of competition

The success of Abraxane has been impacted by the introduction of other chemotherapy drugs, including the approval of Keytruda (pembrolizumab) for certain breast cancer and NSCLC indications [5]. However, Abraxane's niche as a first-line treatment for taxane-resistant breast cancer has helped maintain its market share.

Patent and exclusivity considerations

Abraxane's manufacturer, Celgene (now a part of Bristol Myers Squibb), has been granted patents on the drug's formulation and method of use [6]. As a result, exclusivity for Abraxane is expected to end in 2025, following the expiration of certain key patents.

References:

[1] DrugPatentWatch.com. (2022). Abraxane.

[2] ClinicalTrials.gov. (2022). Paclitaxel albumin-bound nanoparticles.

[3] FDA. (2022). Abraxane.

[4] Celgene. (2022). Abraxane.

[5] FDA. (2022). Keytruda.

[6] US Patent and Trademark Office. (2022). Patent EP2568132.